Evidence for the conversion of docetaxel into 7″-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy.

Czejka, M; Greil, R; Ulsperger, E; Schnait, H; Kienesberger, K; Brumnik, T; Farkouh, A; Schierholz, J; Int J Clin Pharmacol Ther. 2010; 48(7): 483-484.

Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.

Desch, P; Asslaber, D; Kern, D; Schnidar, H; Mangelberger, D; Alinger, B; Stoecher, M; Hofbauer, SW; Neureiter, D; Tinhofer, I; Aberger, F; Hartmann, TN; Greil, R; Oncogene. 2010; 29(35): 488-495.

Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.

Labi, V; Erlacher, M; Krumschnabel, G; Manzl, C; Tzankov, A; Pinon, J; Egle, A; Villunger, A; Genes Dev. 2010; 24(15):1602-1607

Dose-dense therapy improves survival in aggressive non-Hodgkin“s lymphoma.

Fridrik, MA; Hausmaninger, H; Lang, A; Drach, J; Krieger, O; Geissler, D; Michlmayr, G; Ulsperger, E; Chott, A; Oberaigner, W; Greil, R ANN HEMATOL. 2010; 89(3): 273-282.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Ludwig, H; Adam, Z; Hajek, R; Greil, R; Tóthová, E; Keil, F; Autzinger, EM; Thaler, J; Gisslinger, H; Lang, A; Egyed, M; Womastek, I; Zojer, N; J Clin Oncol. 2010; 28(30): 4635-4641.

Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.

Hofbauer, SW; Piñón, JD; Brachtl, G; Haginger, L; Wang, W; Jöhrer, K; Tinhofer, I; Hartmann, TN; Greil, R; Cancer Res. 2010; 70(18):7336-7344

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.

Perkhofer, S; Lass-Flörl, C; Hell, M; Russ, G; Krause, R; Hönigl, M; Geltner, C; Auberger, J; Gastl, G; Mitterbauer, M; Willinger, B; Knöbl, P; Resch, G; Waldner, R; Makrai, A; Hartmann, G; Girschikofsky, M; Greil, R; Int J Antimicrob Agents. 2010; 36(6):531-536

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Michlmayr, A; Bachleitner-Hofmann, T; Baumann, S; Marchetti-Deschmann, M; Rech-Weichselbraun, I; Burghuber, C; Pluschnig, U; Bartsch, R; Graf, A; Greil, R; Allmaier, G; Steger, G; Gnant, M; Bergmann, M; Oehler, R; Br J Cancer. 2010; 103(8): 1201-1208.

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories

Fiegl, M; Erdel, M; Tinhofer, I; Brychtova, Y; Panovska, A; Doubek, M; Eigenberger, K; Fonatsch, C; Hopfinger, G; Muhlberger, H; Zabernigg, A; Falkner, F; Gastl, G; Mayer, J; Greil, R ANN ONCOL. 2010; 21(12): 2410-2419.

Aberrant heterodimerization of keratin 16 with keratin 6A in HaCaT keratinocytes results in diminished cellular migration.

Trost, A; Desch, P; Wally, V; Haim, M; Maier, RH; Reitsamer, HA; Hintner, H; Bauer, JW; Onder, K; MECH AGEING DEV. 2010; 131(5): 346-353.